# Medical Question & Answer

**Sample ID**: e10eee18-3027-4456-bb73-70329505189f
**Dataset Index**: 3555

---

## Question

How to enroll in the CANDOR trial for lupus nephritis?

---

## Answer

> Let's see… What do we have here? The user is asking how to enroll in the CANDOR trial for lupus nephritis. Let's break this down step-by-step. First, I need to think about whether "CANDOR" appears in the provided references and what comparable phase 3 LN trials are documented. Then, I should verify the core eligibility, screening, randomization, and background therapy elements from AURORA that can validly serve as a template. Next, I will outline the monitoring and endpoints structure and ensure it aligns with regulatory-label details and guideline frameworks. Finally, I'll consider what to do if "CANDOR" is different or not captured here, including how to identify active sites and cross-check with guideline-concordant care principles [^11499bBQ] [^115Gc2gt] [^116J6pH1].

> Let me first confirm the trial naming. After scanning the provided citations, I do not see a lupus nephritis trial named "CANDOR"; the core phase 3 data revolve around AURORA 1/2 for voclosporin and BLISS-LN for belimumab. Wait, let me verify before concluding — yes, AURORA 1 is the 52‑week, double-blind, multicenter, randomized, placebo-controlled trial, and BLISS-LN is the 104‑week phase 3 belimumab trial; neither document uses the name "CANDOR", so I should not assume equivalence. I initially wondered if "CANDOR" might be a sponsor code-name for one of these programs, but hold on, that would be speculation without textual support; instead, I will map the enrollment flow to AURORA, which is fully specified and representative of contemporary LN trial operations [^11499bBQ] [^1172Pyf3].

> I will now examine key eligibility features to anchor pre-screening. Inclusion in AURORA required SLE by ACR criteria with biopsy-proven active LN within 2 years showing ISN/RPS class III, IV, or V (alone or in combination), with UPCR thresholds of ≥ 1.5 mg/mg for class III/IV and ≥ 2.0 mg/mg for class V, while typical exclusions included eGFR ≤ 45 mL/min/1.73 m² and significant comorbidities; let me double-check those numbers against the FDA label, which mirrors the AURORA schema and steroid/MMF backbones, and confirm the pathology classification framework via ISN/RPS definitions to ensure consistent biopsy interpretation. Hold on, I should verify age constraints too — AURORA enrolled adults, so I will keep adult-only criteria unless a pediatric protocol is specified. These checkpoints match AURORA and the Lupkynis label, and align with standard biopsy classification guidance used in LN trials [^11499bBQ] [^115Gc2gt] [^112EnfSh].

> Next, I should review how to identify participating sites and the randomization infrastructure. AURORA 1 ran across 142 hospitals and clinics in 27 countries and used an interactive web response system for 1:1 allocation to voclosporin versus placebo on a background of MMF and rapidly tapered low-dose oral steroids; I need to ensure I describe this operationally because it dictates the site contact, eligibility verification, and assignment flow that patients experience during enrollment. If "CANDOR" exists externally, a similar multi-site structure and IWRS randomization would typically apply, but my plan will stay anchored to the AURORA-described framework given the supplied evidence base [^11499bBQ].

> Let me think about the pre-screening and formal screening steps. Practically, pre-screening involves contacting the site investigator or coordinator, sharing documentation of SLE classification, biopsy report within the allowable window, and recent labs, followed by a screening visit with IRB-approved consent, physical exam, labs including urinalysis, serum creatinine/eGFR, complements, and anti-dsDNA, along with confirmation of proteinuria by UPCR or a 24‑hour collection and rigorous medication reconciliation. I should confirm that AURORA explicitly captured these elements — yes, the trial methods and label context reflect these standard screening procedures, including protocol-defined lab schedules and verification of key thresholds prior to randomization [^11499bBQ] [^115Gc2gt].

> I should confirm the background therapy and steroid taper because they are central to both eligibility and on‑study conduct. In AURORA and the Lupkynis label, MMF targeted 2 g/day (with allowance for titration), steroid induction included IV methylprednisolone on Days 1 and 2 at 500 mg/day if body weight ≥ 45 kg or 250 mg/day if < 45 kg, followed by oral prednisone 25 mg/day if ≥ 45 kg or 20 mg/day if < 45 kg, with a taper to a target of 2.5 mg/day by Week 16; wait, I should also verify CNI-related eGFR considerations — protocol guidance specified dose modification for declines in eGFR or rises in BP due to expected hemodynamic effects of calcineurin inhibitors, which is critical for safety and dose management during the trial [^115Gc2gt] [^111gSufQ].

> Now, I will outline randomization, treatment initiation, and follow‑up cadence. After eligibility confirmation, subjects were randomized 1:1 to voclosporin 23.7 mg BID or placebo plus MMF and the standardized glucocorticoid regimen, with baseline pulses and oral taper as above; visits were frequent in year 1, and the primary endpoint in AURORA 1 was complete renal response at 52 weeks defined as UPCR ≤ 0.5 mg/mg, stable renal function (eGFR ≥ 60 mL/min/1.73 m² or ≤ 20% decline from baseline), steroid constraints, and no rescue medication. I should double-check that endpoint definition — yes, that is accurate for AURORA 1, and monitoring emphasized eGFR, proteinuria, BP, and adverse events with prespecified rules for study drug adjustment, which provides a reliable template for expectations during participation [^11499bBQ].

> Hold on, let's not jump to conclusions about background standards of care without cross-referencing guidelines. KDIGO 2024 and ACR 2025 both endorse multi-agent regimens for class III/IV (± V) LN, including options that add a calcineurin inhibitor or belimumab to a mycophenolate-based backbone, and they frame steroid pulses followed by taper within structured targets; while these are not "trial enrollment" rules, aligning trial backbones with guideline-concordant therapy helps ensure clinical plausibility and safety context during enrollment decisions, especially when dual versus triple therapy decisions arise in protocol amendments or site practice. I should confirm the proteinuria-based triggers for CNI inclusion in guidelines — yes, KDIGO notes CNI-containing regimens when kidney function is relatively preserved and proteinuria is heavy, and ACR supports triple regimens, particularly when proteinuria is ≥ 3 g/g or extra-renal disease favors belimumab augmentation [^116J6pH1] [^111LbAtp].

> But wait, what if "CANDOR" is a distinct protocol outside these documents. I need to ensure the user has a pathway to verify real-time opportunities: cross-check ClinicalTrials.gov for lupus nephritis and filter by recruiting status, contact major academic rheumatology/nephrology centers, and coordinate with the treating rheumatologist for referral and record collation; operationally, the screening and consent steps will mirror what AURORA and BLISS-LN implemented, including biopsy verification windows, renal function thresholds, standardized background immunosuppression, and safety monitoring, so the process described here should generalize with minor protocol-specific adjustments. As a reality check, BLISS‑LN demonstrates similar large-trial screening rigor and long-term renal endpoints, reinforcing that the flow I've outlined is representative of modern LN trials even when the investigational agent differs [^1172Pyf3] [^11499bBQ].

> Final check and synthesis: the provided corpus does not document a lupus nephritis trial named "CANDOR", so modeling the enrollment process on AURORA is appropriate and evidence-based. The stepwise flow is: verify SLE and biopsy class within window with proteinuria thresholds, pre-screen and consent, confirm labs and concomitant therapies, randomize via IWRS, initiate protocolized MMF and steroid taper with or without investigational agent, and follow on a frequent schedule with safety-triggered dose adjustments and a 52‑week renal response endpoint; guideline frameworks from KDIGO and ACR support the therapeutic architecture embedded in these trials, especially for class III/IV (± V) disease with significant proteinuria. If "CANDOR" is different or active elsewhere, the user should validate the protocol-specific inclusion/exclusion and site list, but the operational core will remain as described here based on AURORA 1 and aligned guidance [^11499bBQ] [^115Gc2gt] [^116J6pH1].

---

I can't locate a lupus nephritis trial named "CANDOR". Please confirm the exact trial name or provide a registry ID (e.g. NCT number), sponsor, or the therapy being studied.

If you meant one of the following trials, **I can provide the enrollment criteria**. **AURORA 1 (voclosporin)** [^11499bBQ] included patients with biopsy-proven class III/IV (± V) or class V LN and specified UPCR thresholds and eGFR requirements. **BLISS-LN (belimumab)** [^1172Pyf3] enrolled patients with biopsy-proven class III/IV (± V) or class V LN who had active renal disease requiring standard therapy [^116ci6Vz].

---

## References

### Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [^11499bBQ]. Lancet (2021). High credibility.

Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults with lupus nephritis, improved complete renal response rates in patients with lupus nephritis in a phase 2 trial. This study aimed to evaluate the efficacy and safety of voclosporin for the treatment of lupus nephritis.

- **Methods**: This multicentre, double-blind, randomised phase 3 trial was conducted in 142 hospitals and clinics across 27 countries. Patients with a diagnosis of systemic lupus erythematosus with lupus nephritis according to the American College of Rheumatology criteria, and a kidney biopsy within 2 years that showed class III, IV, or V (alone or in combination with class III or IV) were eligible. Patients were randomly assigned (1:1) to oral voclosporin (23.7 mg twice daily) or placebo, on a background of mycophenolate mofetil (1 g twice daily) and rapidly tapered low-dose oral steroids, by use of an interactive web response system.

	- **Primary endpoint**: Complete renal response at 52 weeks was defined as a composite of urine protein creatinine ratio of 0.5 mg/mg or less, stable renal function (defined as estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m² or no confirmed decrease from baseline in eGFR of > 20%), no administration of rescue medication, and no more than 10 mg prednisone equivalent per day for 3 or more consecutive days or for 7 or more days during weeks 44 through 52, just before the primary endpoint assessment.

	- **Safety assessment**: Safety was also assessed. Efficacy analysis was performed by intention-to-treat and safety analysis by randomised patients receiving at least one dose.

---

### Lupkynis [^115Gc2gt]. U.S. Food and Drug Administration (2024). High credibility.

The safety and efficacy of Lupkynis were investigated in Study 1 (NCT03021499), a 52-week, randomized, double-blind, placebo-controlled trial in patients diagnosed with systemic lupus erythematosus. This included patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) biopsy-proven active Class III or IV lupus nephritis (LN), either alone or in combination with Class V LN, as well as patients with Class V LN. Patients with Class III or IV LN (alone or combined with Class V LN) were required to have a urine protein to creatinine (UPCR) ratio of ≥ 1.5 mg/mg, while those with Class V LN needed a UPCR of ≥ 2 mg/mg.

A total of 357 patients with LN were randomized in a 1:1 ratio to receive either Lupkynis 23.7 mg twice daily or a placebo. Patients in both treatment arms received background treatment with mycophenolate mofetil (MMF) and corticosteroids as follows:

- **MMF regimen**: Oral MMF at a target dose of 2 g/day (1 g twice a day). Patients not already receiving MMF were started on MMF 500 mg twice a day, escalating to 1 g twice a day after the first week. Dose increases up to 3 g/day were allowed.

- **Corticosteroid regimen**: Intravenous (IV) methylprednisolone on Day 1 and Day 2 at a dose of 500 mg/day for those with a body weight ≥ 45 kg or 250 mg/day for body weight < 45 kg. This was followed by a reducing taper of oral corticosteroids — oral prednisone 25 mg/day for body weight ≥ 45 kg or 20 mg/day for body weight < 45 kg — tapered to achieve a target dose of 2.5 mg/day by Week 16.

---

### Benlysta [^1172Pyf3]. U.S. Food and Drug Administration (2024). High credibility.

The safety and effectiveness of Benlysta 10 mg/kg, administered intravenously over 1 hour on Days 0, 14, 28, and then every 28 days plus standard therapy, were evaluated in a 104-week, randomized, double-blind, placebo-controlled trial in 448 patients with active proliferative and/or membranous lupus nephritis. The patients had a clinical diagnosis of SLE according to American College of Rheumatology classification criteria; biopsy-proven lupus nephritis Class III, IV, and/or V; and active renal disease at screening requiring standard therapy: corticosteroids with 1) mycophenolate for induction followed by mycophenolate for maintenance or 2) cyclophosphamide for induction followed by azathioprine for maintenance. This trial was conducted in Asia, North America, South America, and Europe. The mean age of patients was 33 years (range: 18 to 77); the majority (88%) were female.

The primary efficacy endpoint was the Primary Efficacy Renal Response (PERR) at Week 104, defined as a response at Week 100 confirmed by a repeat measurement at Week 104 of the following parameters: urine protein:creatinine ratio (uPCR) ≤ 0.7 g/g and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m² or no decrease in eGFR of > 20% from the pre-flare value.

---

### Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria [^111i72rJ]. Clinical Journal of the American Society of Nephrology (2024). High credibility.

Overall, 127 participants (86%) completed the study, with 90% and 82% of the voclosporin and control arms, respectively. Of these, 71% and 61% of each arm, respectively, completed one year of study drug treatment. The mean (SD) duration of exposure to the study drug was similar for both voclosporin- and control-treated participants, with 317 (98) days and 294 (111) days, respectively. Exposure to MMF was comparable, with a mean (SD) final dose of 1.84 g/d (0.54) in the voclosporin arm and 1.92 g/d (0.56) in the control arm.

Similar proportions of participants in the voclosporin and control arms were on oral prednisone (or equivalent) doses of ≤ 2.5 mg/d at six months (87% and 86%, respectively) and 12 months (66% and 70%, respectively). The mean (SD) duration of exposure to oral glucocorticoids in the voclosporin and control arms was 342 days (86) and 329 days (98), respectively.

- **Renal response endpoints**: Compared with the control arm (10%), a greater proportion of patients treated with voclosporin achieved a complete renal response at six months (20%, OR, 2.18; 95% CI, 0.83 to 5.67; P = 0.11). At 12 months, 34% of patients in the voclosporin arm had achieved a complete renal response compared with 11% in the control arm (OR, 4.43; 95% CI, 1.78 to > 9.99; P = 0.001). Similarly, higher proportions of voclosporin-treated participants achieved a partial renal response at six and 12 months compared with the control arm. There was also a treatment benefit observed with voclosporin in patients in the AURORA 1 study with UPCR < 3 g/g, with 49% of voclosporin-treated patients experiencing improvement.

---

### A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis [^111yS7JR]. Arthritis & Rheumatology (2016). High credibility.

To assess the efficacy and safety of sirukumab, an anti–interleukin‐6 monoclonal antibody, researchers conducted a study on patients with active lupus nephritis (LN). Patients with class III or class IV LN, as determined by renal biopsy within 14 months of randomization, who had persistent proteinuria (> 0.5 gm/day) despite receiving immunosuppressive therapy and were being treated with stable doses of a renin‐angiotensin system blocker, were randomized (5:1) to receive treatment with sirukumab at a dose of 10 mg/kg intravenously (n = 21) or placebo (n = 4) every 4 weeks through week 24. The primary endpoint was the percent reduction in proteinuria, measured as the protein‐to‐creatinine (P:C) ratio in a 12‐hour urine collection, from baseline to week 24.

Twenty-five patients were enrolled, of whom 19 (76.0%) completed treatment through week 24, and 6 (24.0%) discontinued the study agent early, with 5 of the 6 discontinuing due to adverse events. At week 24, the median percent change in proteinuria from baseline in sirukumab-treated patients was 0.0% (95% confidence interval -61.8, 39.6). Conversely, the 4 placebo-treated patients showed an increase in proteinuria (median percent reduction -43.3%) at week 24. Notably, a subset of 5 sirukumab-treated patients had ≥ 50% improvement in their P:C ratio through week 28. In the sirukumab group, 47.6% of patients experienced ≥ 1 serious adverse event through week 40, most of which were infection-related. No deaths or malignancies occurred. No serious adverse events were observed in the 4 placebo-treated patients.

---

### KDIGO 2024 clinical practice guideline for the management of lupus nephritis [^116UBtKN]. Kidney International (2024). High credibility.

Regarding medical management for lupus nephritis, specifically with respect to immunosuppressive therapy for pure class V LN, the KDIGO 2024 guidelines recommend monitoring the level of proteinuria and preventing or treating complications such as thrombosis, dyslipidemia, and edema in patients with pure class V LN.

---

### Safety and efficacy of belimumab in patients with lupus nephritis: Open-label extension of BLISS-LN study [^111J2yWA]. Clinical Journal of the American Society of Nephrology (2022). Low credibility.

In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed belimumab's safety and efficacy.

- **Design, setting, participants, & measurements**: Eligible patients completing BLISS-LN received monthly intravenous belimumab 10 mg/kg plus standard therapy. End points included safety, open-label week 28 primary efficacy renal response (urine protein-creatinine ratio [UPCR] ≤ 0.7, eGFR no more than 20% below open-label baseline value or ≥ 60 ml/min per 1.73 m², no prohibited medications) and complete renal response (UPCR < 0.5, eGFR no more than 10% below open-label baseline value or ≥ 90 ml/min per 1.73 m², no prohibited medications), and UPCR and eGFR by visit. Responses were also analyzed post hoc using the double-blind phase criteria.

- **Results**: Of 257 enrolled patients, 255 were treated (safety population: n = 123 switched from placebo-to-belimumab; n = 132 remained on belimumab); 245 (97%) patients completed the study. Adverse events and serious adverse events were experienced by 62% and 4% of placebo-to-belimumab patients, respectively, and by 70% and 8% of belimumab-to-belimumab patients, respectively. One death occurred in the placebo-to-belimumab group. From open-label baseline to week 28, increases occurred in the proportions of patients achieving primary efficacy renal response (placebo-to-belimumab: from 60% to 67%; belimumab-to-belimumab: from 70% to 75%) and complete renal response (placebo-to-belimumab: from 36% to 48%; belimumab-to-belimumab: from…

---

### Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial [^114gjQQA]. Arthritis & Rheumatology (2024). Low credibility.

The AURORA 2 study evaluated the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one-year AURORA 1 study.

Enrolled patients continued their double-blinded treatment of voclosporin or placebo, which was randomly assigned in AURORA 1, in combination with mycophenolate mofetil and low-dose glucocorticoids. The primary objective was safety, assessed through adverse events (AEs) and biochemical and hematological evaluations. Efficacy was measured by renal response.

A total of 216 patients enrolled in AURORA 2. The treatment was well tolerated, with 86.1% of participants completing the study and no unexpected safety signals. Adverse events occurred in 86% and 80% of patients in the voclosporin and control groups, respectively. The AE profile was similar to that seen in AURORA 1, albeit with reduced frequency. Investigator-reported AEs, such as a decrease in glomerular filtration rate (GFR) and hypertension, occurred more frequently in the voclosporin group than in the control group (10.3% vs. 5.0%, and 8.6% vs. 7.0%, respectively).

The mean corrected estimated GFR (eGFR) was within the normal range and stable in both treatment groups. The eGFR slope over the two-year period was -0.2 mL/min/1.73 m² (95% confidence interval [CI] -3.0 to 2.7) in the voclosporin group and -5.4 mL/min/1.73 m² (95% CI -8.4 to -2.3) in the control group. Improved proteinuria persisted across three years of treatment, leading to more frequent complete renal responses in patients treated with voclosporin (50.9%).

---

### Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria [^111gSufQ]. Clinical Journal of the American Society of Nephrology (2024). High credibility.

This study is a post hoc analysis of AURORA 1, a phase 3, randomized, prospective, placebo-controlled, double-blind, multicenter, international, two-arm comparison trial conducted between May 2017 and October 2019.

Study design and methods have previously been described. In brief, participants were randomly assigned (1:1) to either oral voclosporin 23.7 mg twice daily or to matching placebo; all participants received MMF (target dose of 2 g/d) and oral glucocorticoids. Glucocorticoids were administered according to a protocol-defined tapering schedule: intravenous methylprednisolone on days 1 and 2, then oral prednisone on day 3, starting at 20–25 mg/d and decreasing to 2.5 mg/d by week 16. Owing to the expected hemodynamic effects of calcineurin inhibitors on eGFR, the protocol provided guidance for study drug dose modification for participants experiencing decreases in eGFR or increases in BP.

As part of the AURORA 1 study implementation, an institutional review board or independent ethics committee at each participating site approved the informed consent form and protocol. All participants provided written informed consent in accordance with the Declaration of Helsinki.

Participants enrolled in the AURORA 1 trial were 18 years and older, diagnosed with active lupus nephritis with a kidney biopsy within the previous 2 years demonstrating class III, IV, or V (alone or in combination with class III or IV) lupus nephritis, had proteinuria ≥ 1.5 g/g (≥ 2 g/g for class V).

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^1112geL4]. Arthritis Care & Research (2025). High credibility.

Regarding diagnostic procedures for lupus nephritis, more specifically with respect to kidney biopsy, the ACR 2025 guidelines recommend performing a prompt kidney biopsy in patients with SLE when LN is suspected, unless contraindicated or not feasible.

---

### KDIGO 2024 clinical practice guideline for the management of lupus nephritis [^1174vtzb]. Kidney International (2024). High credibility.

Regarding the medical management of lupus nephritis, particularly with respect to immunosuppressive therapy for class III-V LN, the KDIGO 2024 guidelines recommend considering the preference of an immunosuppressive regimen that includes a calcineurin inhibitor (voclosporin, tacrolimus, or cyclosporine). This is advised for initial therapy in patients with relatively preserved kidney function and nephrotic range proteinuria likely due to extensive podocyte injury, as well as in patients unable to tolerate standard-dose mycophenolic acid analogs or those unfit for cyclophosphamide-based regimens.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^117WaHvy]. Arthritis Care & Research (2025). High credibility.

Regarding diagnostic procedures for lupus nephritis, specifically with respect to kidney biopsy, the ACR 2025 guidelines recommend considering a repeat kidney biopsy in patients with treated lupus nephritis in remission who present with suspected lupus nephritis flare (increased proteinuria, hematuria, and/or worsening kidney function). It is also recommended for patients who have had ≥ 6 months of appropriate treatment and are experiencing ongoing or worsening proteinuria, hematuria, and/or decreased kidney function.

---

### 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [^114VCgzH]. Annals of the Rheumatic Diseases (2020). High credibility.

With regard to medical management for lupus nephritis, specifically concerning immunosuppressive therapy for pure class V LN, the ERA-EDTA/EULAR 2020 guidelines recommend initiating corticosteroids and immunosuppression in patients with pure class V nephritis with nephrotic-range proteinuria (2b/B) or if the urine protein-to-creatinine ratio exceeds 1,000 mg/g, despite the optimal use of RAAS blockers.

---

### SGLT-2 inhibitors: new horizons for rheumatologists [^114VBeTz]. Current Opinion in Rheumatology (2024). High credibility.

Interest in the use of SGLT2 inhibitors has expanded to other glomerulonephropathies, particularly lupus nephritis, a glomerulonephropathy in which immunosuppression plays a clearly defined role. Small studies have identified both the safety and efficacy of SGLT2 inhibitor use in lupus nephritis.

A study by Wang et al. showed that the addition of dapagliflozin to standard therapy in patients with systemic lupus erythematosus (SLE) was well tolerated in a phase I/II trial. This study enrolled 38 patients with SLE, 17 (44.7%) of whom had active lupus nephritis, defined as proteinuria more than 0.5 g/24 h. Dapagliflozin 10 mg was added to standard care, and patients were monitored for the following six months. Eight patients (21%) experienced adverse events leading to drug discontinuation, although only half of these events were attributed to dapagliflozin. One major lupus flare was recorded. Only one lower urinary tract infection was observed (2.63% of patients). Secondary endpoints included the SLE disease activity index, which decreased over the course of the study (SLEDAI 4.24→3.97), but was not statistically significant. From baseline to 6-month follow-up, the mean daily prednisone dose decreased by 30% (14.21 to 10.67 mg). The median 24-hour urine protein remained unchanged in the patients with active lupus nephritis throughout the course of the study.

---

### Accelerating medicines partnership: Organizational structure and preliminary data from the phase 1 studies of lupus nephritis [^1115fztZ]. Arthritis Care & Research (2020). High credibility.

The Accelerating Medicines Partnership (AMP) Lupus Network was established as a collaboration between the National Institutes of Health, pharmaceutical companies, nonprofit stakeholders, and lupus investigators across multiple academic centers. The goal was to apply high-throughput technologies to the analysis of renal tissue, urine, and blood from patients with lupus nephritis (LN). The AMP network offers publicly accessible data to the community, aiming to generate new scientific hypotheses and improve diagnostic and therapeutic tools to enhance disease outcomes. This paper presents a description of the structure of the AMP Lupus Network and a summary of the preliminary results from the phase 1 studies. The successful completion of phase 1 sets the stage for the analysis of a large cohort of LN samples in phase 2 and serves as a model for establishing similar discovery cohorts.

---

### A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis [^116Xpbqh]. Arthritis & Rheumatology (2016). Low credibility.

The objective of this study was to assess the efficacy and safety of sirukumab, an anti-interleukin-6 monoclonal antibody, for the treatment of patients with active lupus nephritis (LN).

- **Methods**: Patients with class III or class IV LN, as determined by renal biopsy within 14 months of randomization, who had persistent proteinuria (> 0.5 gm/day) despite receiving immunosuppressive therapy and who were being treated with stable doses of a renin-angiotensin system blocker, were randomized (5:1) to receive treatment with sirukumab at a dose of 10 mg/kg intravenously (n = 21) or placebo (n = 4) every 4 weeks through week 24. The primary endpoint was the percent reduction in proteinuria, measured as the protein-to-creatinine (P:C) ratio in a 12-hour urine collection, from baseline to week 24.

- **Results**: Twenty-five patients were enrolled, of whom 19 (76.0%) completed treatment through week 24, and 6 (24.0%) discontinued the study agent early, with 5 of the 6 discontinuing due to adverse events. At week 24, the median percent change in proteinuria from baseline to week 24 in sirukumab-treated patients was 0.0% (95% confidence interval: -61.8, 39.6). In contrast, the 4 placebo-treated patients showed an increase in proteinuria (median percent reduction -43.3%) at week 24. Of note, a subset of 5 sirukumab-treated patients had ≥ 50% improvement in their P:C ratio through week 28. In the sirukumab group, 47.6% of patients experienced ≥ 1 serious adverse event through week 40; most were infection-related. No deaths or malignancies occurred. No serious adverse events were observed in the 4 placebo-treated patients.

---

### Revision of the International Society of Nephrology/renal pathology society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices [^112EnfSh]. Kidney International (2018). High credibility.

In the classification and risk stratification for lupus nephritis, the 2018 ISN/RPS guidelines recommend classifying LN according to the International Society of Nephrology/Renal Pathology Society classification as follows:

- **Class I, minimal mesangial LN**: Normal glomeruli by light microscopy, but mesangial immune deposits are present by immunofluorescence.

- **Class II, mesangial proliferative LN**: Characterized by purely mesangial hypercellularity (≥ 4 nuclei fully surrounded by matrix in the mesangial area, not including the hilar region) or mesangial matrix expansion by light microscopy. Mesangial immune deposits are present. A few isolated subepithelial or subendothelial deposits may be visible by immunofluorescence or electron microscopy, but not by light microscopy.

- **Class III, focal lupus nephritis**:
	- Active or inactive focal, segmental, or global endo- or extracapillary glomerulonephritis.
	- **Class III (A) - Active lesions**: Focal proliferative LN.
	- **Class III (A/C) - Active and chronic lesions**: Focal proliferative and sclerosing LN.
	- **Class III (C) - Chronic inactive lesions with glomerular scars**: Focal sclerosing LN.

- **Class IV, diffuse LN**: Includes active or inactive diffuse, segmental, or global endo- or extracapillary glomerulonephritis involving ≥ 50% of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial alterations.

---

### Phase III/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus [^1171zWb6]. Arthritis & Rheumatology (2022). Low credibility.

In the double-blind phase, among patients with baseline SELENA–SLEDAI–SLEDAI‐2K renal involvement, more patients in the belimumab group (41.8% [23 of 55]) experienced improvement in this domain compared with those in the placebo group (20.6% [7 of 34]). Among those without baseline SELENA–SLEDAI–SLEDAI‐2K renal involvement, the percentage of patients who experienced worsening in this domain was low in both groups (6.1% [15 of 244] in the belimumab group; 7.8% [9 of 115] in the placebo group).

Changes in proteinuria by visit in patients in the double-blind phase with baseline proteinuria > 0.5 gm/24 hours are shown in Supplementary Figure 4. The median percentage change in proteinuria at week 52 among patients with baseline proteinuria > 0.5 gm/24 hours was numerically greater with belimumab treatment compared with placebo (−65.27% [interquartile range −81.1, −38.8], n = 38 versus −32.89% [interquartile range −76.6, 36.3], n = 23).

Among patients with baseline proteinuria > 0.5 gm/24 hours in the open-label extension phase, the median percentage change in proteinuria at open-label extension week 24 was −73.99% (interquartile range −91.3, −36.4) in 34 patients receiving continuous belimumab since the start of the double-blind phase and −34.30% (interquartile range −58.8, 29.4) in 17 patients who switched from placebo to belimumab at the start of the open-label extension phase. At week 52 of the double-blind phase, 16 patients (42.1%) in the belimumab group and 6 (26.1%) in the placebo group with baseline proteinuria > 0.5 gm/24 hours experienced a downward shift in proteinuria.

---

### Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria [^113RoxFW]. Clinical Journal of the American Society of Nephrology (2024). High credibility.

- **Efficacy end points**: Efficacy end points included complete renal response, defined as a composite end point of UPCR ≤ 0.5 g/g with eGFR ≥ 60 ml/min per 1.73 m² or no decrease > 20% from baseline, use of low-dose glucocorticoids (defined as no more than 10 mg prednisone equivalent per day for ≥ 3 consecutive days or for ≥ 7 days in the 8 weeks before the end point assessment), and no use of rescue medication. Partial renal response was defined as a ≥ 50% reduction in UPCR from baseline. Additionally, time to ≥ 50% reduction in UPCR from baseline, time to UPCR ≤ 0.5 g/g, and mean UPCR over time were analyzed. A masked, independent Clinical Endpoints Committee adjudicated the end point of complete renal response at 6 and 12 months, based on an assessment of UPCR, eGFR, steroid dose, rescue and prohibited medications, and adverse events for each participant. Changes from baseline in UPCR and changes from screening visit in immunology parameters (complement 3, complement 4, and anti–double-stranded deoxyribonucleic acid) were also assessed.

- **Safety end points**: Safety end points included adverse events, reported at the discretion of the study investigator using preferred terms aggregated by System Organ Class in the Medical Dictionary for Regulatory Activities version 20.0, and biochemical and hematologic laboratory assessments. Adverse events by the preferred term of GFR decreased were reductions in eGFR determined to be clinically relevant at the discretion of the study investigator and were not based on a specific magnitude of reduction from baseline. Laboratory-confirmed decreases in eGFR of ≥ 30% from baseline were noted.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^111Q8628]. Arthritis Care & Research (2025). High credibility.

Regarding medical management for lupus nephritis, specifically in terms of immunosuppressive therapy for class III-V lupus nephritis (LN), the ACR 2025 guidelines recommend considering escalation to a triple immunosuppressive regimen in patients achieving only a partial renal response with dual immunosuppressive therapy. This dual therapy consists of a corticosteroid combined with either cyclophosphamide or a mycophenolic acid analog.

---

### American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis [^112K4Rn5]. Arthritis Care & Research (2012). High credibility.

Regarding screening and diagnosis for lupus nephritis, particularly with respect to diagnostic criteria, the ACR 2012 guidelines recommend defining lupus nephritis according to the ACR classification criteria.

---

### Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the Phase 3 AURORA 2 clinical trial [^116AzksW]. Arthritis & Rheumatology (2024). High credibility.

The AURORA 2 study, published by Amit Saxena and colleagues in 2023 in the journal Arthritis & Rheumatology, examines lupus nephritis and the effects of long-term voclosporin treatment in patients with this condition.

- **Study design**: A multi-center, double-blinded, randomized controlled trial (RCT) was conducted.

- **Population**: The study included 216 patients (193 female, 23 male). Inclusion criteria required adult patients with lupus nephritis needing ongoing immunosuppressive therapy. Key exclusion criteria included eGFR ≤ 45 mL/min, congenital or acquired immunodeficiency, lymphoproliferative disease or prior total lymphoid irradiation, as well as severe cardiovascular disease, liver dysfunction, or COPD or asthma necessitating oral corticosteroids.

- **Interventions**: Participants were divided into two groups: 116 received voclosporin (23.7 mg BID for an additional two years), while 100 received a matching placebo for the same duration.

- **Primary outcome**: A borderline significant increase in complete renal response was observed (50.9% vs. 39%; OR 1.74, 95% CI 1 to 3.03).

- **Secondary outcomes**: There was no significant difference in partial renal response (74.1% vs. 69%; OR 1.39, 95% CI 0.75 to 2.58) and no significant difference in renal flare (23.8% vs. 26%; OR 0.85, 95% CI 0.42 to 1.73). However, a significant increase in good renal outcome was noted (66.4% vs. 54%; OR 1.78, 95% CI 1.01 to 3.12).

- **Safety outcomes**: There was no significant difference in adverse and serious adverse events between the groups.

---

### 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [^114AZJCK]. Annals of the Rheumatic Diseases (2020). High credibility.

The 2020 ERA-EDTA/EULAR guidelines for medical management of lupus nephritis, particularly regarding immunosuppressive therapy for class III-V lupus nephritis (LN), recommend considering the initiation of the same treatment in patients who are at high risk for kidney failure. This includes those with reduced glomerular filtration rate (GFR) and histological findings such as crescents, fibrinoid necrosis, or severe interstitial inflammation.

---

### Lupus nephritis: Clinical presentations and outcomes in the 21st century [^115tMKPr]. Rheumatology (2020). Low credibility.

**Rheumatology key messages**: LN is still a risk factor for chronic kidney injury and end-stage renal disease in SLE. Kidney biopsy is fundamental to characterize the renal involvement and define the patient prognosis. New target therapies are under evaluation and may provide effective alternatives to currently available treatments.

---

### Update on lupus nephritis [^1171o5uJ]. Clinical Journal of the American Society of Nephrology (2017). High credibility.

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that affects the kidneys in about 50% of patients. Lupus nephritis is a major risk factor for overall morbidity and mortality in SLE, and despite potent anti-inflammatory and immunosuppressive therapies, it still ends in chronic kidney disease (CKD) or end-stage renal disease (ESRD) for too many patients. This review highlights recent updates in our understanding of disease epidemiology, genetics, pathogenesis, and treatment in an effort to establish a framework for lupus nephritis management that is patient-specific and oriented toward maintaining long-term kidney function in patients with lupus.

---

### A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis [^1118pYVp]. Kidney International (2019). High credibility.

Calcineurin inhibitors added to standard-of-care induction therapy for lupus nephritis (LN) may increase complete renal remission (CRR) rates. The AURA-LV study tested the novel calcineurin inhibitor voclosporin for efficacy and safety in active LN. AURA-LV was a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial of two doses of voclosporin (23.7 mg or 39.5 mg, each twice daily) versus placebo in combination with mycophenolate mofetil (2 g/d) and rapidly tapered low-dose oral corticosteroids for inducing remission in LN. The primary endpoint was CRR at 24 weeks, and the secondary endpoint was CRR at 48 weeks.

Two hundred sixty-five subjects from 79 centers in 20 countries were recruited and randomized to treatment for 48 weeks. CRR at week 24 was achieved by 29 (32.6%) subjects in the low-dose voclosporin group, 24 (27.3%) subjects in the high-dose voclosporin group, and 17 (19.3%) subjects in the placebo group (OR = 2.03 for low-dose voclosporin versus placebo). The significantly greater CRR rate in the low-dose voclosporin group persisted at 48 weeks, and CRRs were also significantly more common in the high-dose voclosporin group compared to placebo at 48 weeks.

There were more serious adverse events in both voclosporin groups and more deaths in the low-dose group compared to placebo and high-dose voclosporin groups (11.2%, 1.1%, and 2.3%, respectively). These results suggest that the addition of low-dose voclosporin to mycophenolate mofetil and corticosteroids for induction therapy of active LN results in a superior renal response compared to mycophenolate mofetil and corticosteroids alone.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^113eLVSy]. Arthritis Care & Research (2025). High credibility.

Regarding diagnostic investigations for lupus nephritis, and specifically with respect to initial evaluation, ACR 2025 guidelines recommend obtaining a thorough evaluation to exclude alternative etiologies of kidney dysfunction in patients with SLE. This includes non-inflammatory causes such as hypertensive, diabetic, and medication-induced nephropathy.

---

### The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021 [^1134Q3Ud]. Nephrology Dialysis Transplantation (2023). High credibility.

In 2019 and 2021, the European League for Rheumatism (EULAR), jointly with the European Renal Association (ERA) and the Kidney Disease: Improving Global Outcomes (KDIGO), respectively, released updated guidelines on the management of lupus nephritis (LN). The Immunology Working Group of the ERA reviewed and compared both updates.

Recommendations were either consistent or the differences were of negligible clinical relevance for the indication for kidney biopsy, kidney biopsy interpretation, treatment targets, hydroxychloroquine dosing, first-line initial immunosuppressive therapy for active class III, IV (± V) LN, pregnancy in LN, LN in pediatric patients, and LN patients with kidney failure.

- **Relevant differences**: These relate to the recognition of lupus podocytopathies, uncertainties in steroid dosing, drug preferences in specific populations and maintenance therapy, treatment of pure class V LN, therapy of recurrent lupus nephritis (reLN), evolving alternative drug options, and the diagnostic work-up of thrombotic microangiopathy.

Altogether, both documents provide excellent guidance to the growing complexity of LN management. This article endeavors to prevent confusion by identifying differences and clarifying discrepancies.

---

### Mock recruitment for the study of antimalarials in an incomplete lupus erythematosus trial [^1114xvqv]. Arthritis Care & Research (2019). Low credibility.

Recruitment to randomized clinical trials is expensive and often falls short of goals, limiting achievement of measurable outcomes. To prepare for a trial in patients with incomplete forms of lupus, a mock recruitment protocol was carried out at four proposed study sites, with the objective to determine levels of interest in patients and to uncover potential barriers to enrollment.

- **Methods**: After obtaining institutional review board approval, study coordinators approached individuals who generally fit proposed criteria for the trial. A standardized script was followed in a structured interview. Levels of interest were determined and any reasons for concerns were collected with an open-ended format.

- **Results**: A total of 45 subjects were interviewed, of which 73% expressed an interest in the trial and 64% said they were likely to enroll. Concerns of those who were not interested included risk of hydroxychloroquine, desire not to receive placebo, and lack of time for participation.

- **Conclusion**: The mock recruitment suggests that the trial will be attractive to suitable patients. The concerns raised support other data indicating that provision of information is crucial to achieving enrollment goals. Mock recruitment of potential investigators should be considered also to address referral concerns.

---

### 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [^1123DTNa]. Annals of the Rheumatic Diseases (2020). High credibility.

Regarding medical management for lupus nephritis, and more specifically with respect to immunosuppressive therapy, the ERA-EDTA/EULAR 2020 guidelines recommend considering the initiation of intravenous cyclophosphamide or calcineurin inhibitors, especially tacrolimus, either in monotherapy or in combination with mycophenolate mofetil/mycophenolic acid. These are proposed as alternative options for patients with class V nephritis, particularly those with nephrotic-range proteinuria.

---

### Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria [^11338aZk]. Clinical Journal of the American Society of Nephrology (2024). High credibility.

This post hoc analysis of the Phase 3 AURORA 1 clinical trial evaluated the efficacy and safety of voclosporin in a subgroup of 148 participants with proliferative lupus nephritis and high levels of proteinuria. In this study, participants treated with voclosporin achieved significantly higher rates of complete renal response at 12 months than participants treated with placebo when administered in combination with MMF and low-dose glucocorticoids. In addition, treatment with voclosporin was associated with earlier and greater reductions in proteinuria that were maintained throughout the study.

Guidelines for the management of lupus nephritis recommend targeting a UPCR of 9.99; P = 0.001 versus 2.65; 95% CI, 1.64 to 4.27; P < 0.0001 in AURORA 1. Furthermore, these complete renal response rates were obtained using a novel glucocorticoid tapering regimen where participants may have received IV glucocorticoids on days 1 and 2 and then initiated oral glucocorticoids at a dose of only 20–25 mg/d on day 3.

---

### 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [^114p3igZ]. Annals of the Rheumatic Diseases (2020). High credibility.

Regarding medical management for lupus nephritis, specifically with respect to immunosuppressive therapy for class III-V lupus nephritis, the ERA-EDTA/EULAR 2020 guidelines recommend initiating immunosuppressive agents in combination with corticosteroids in patients with class IIIA or IIIA/C (± V) and IVA or IVA/C (± V) nephritis.

---

### 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [^113MaBJf]. Annals of the rheumatic diseases (2020). High credibility.

Regarding medical management for lupus nephritis, specifically concerning immunosuppressive therapy for class III-V LN, the ERA-EDTA/EULAR 2020 guidelines recommend initiating mycophenolate mofetil (target dose of 2–3 g/day, or mycophenolic acid at an equivalent dose) or low-dose IV cyclophosphamide (500 mg every 2 weeks for a total of 6 doses) in combination with corticosteroids in patients with class III or IV (± V) LN.

---

### American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis [^111tdTpL]. Arthritis Care & Research (2012). High credibility.

Regarding specific circumstances for lupus nephritis, particularly concerning pregnant patients, the ACR 2012 guidelines recommend obtaining the following investigations every month in pregnant patients with active lupus nephritis at the onset of treatment: blood pressure, urinalysis, urine protein-to-creatinine ratio, serum creatinine, C3/C4 levels, and anti-DNA levels.

---

### Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: Post hoc subgroup analyses of the phase 3 BLISS-LN trial [^116ci6Vz]. Nephrology, Dialysis, Transplantation (2023). High credibility.

Data on belimumab efficacy in patients with lupus nephritis (LN) according to diagnosis duration or induction therapy are limited. Post hoc analyses of the phase 3, randomized, double-blind BLISS-LN study (GSK BEL114054; NCT01639339) were performed to assess belimumab efficacy on kidney-related outcomes in newly diagnosed and relapsed LN subgroups and according to the use of glucocorticoid (GC) pulses at induction.

- **Methods**: BLISS-LN randomized 448 patients with active LN to receive monthly intravenous belimumab 10 mg/kg or placebo plus standard therapy. Post hoc analyses assessed primary efficacy renal response (PERR) and complete renal response (CRR) at week 104, time to kidney-related event or death, and time to first LN flare from week 24 in newly diagnosed and relapsed patients, and patients with or without GC pulses at induction.

- **Results**: A greater proportion of patients achieved a PERR with belimumab versus placebo in the newly diagnosed (69/148 [46.6%] versus 55/148 [37.2%]; odds ratio [OR] 1.36 [95% confidence interval (CI) 0.85–2.20]) and relapsed (27/75 [36.0%] versus 17/75 [22.7%]; OR 2.31 [95% CI 1.07–5.01]) subgroups. Similarly for CRR: newly diagnosed (50/148 [33.8%] versus 36/148 [24.3%]; OR 1.49 [95% CI 0.88–2.51]) and relapsed (17/75 [22.7%] versus 8/75 [10.7%]; OR 3.11 [95% CI 1.16–8.31]). The probability of kidney-related event or death, or LN flare was lower with belimumab versus placebo in both subgroups. Belimumab was associated with improved kidney outcomes versus placebo with or without GC pulses at induction.

- **Conclusion**: Data suggest consistent benefits with belimumab for kidney outcomes in patients with lupus nephritis. [The conclusion ends prematurely in the original text and should be treated as such.]

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^1131g8T3]. Arthritis & Rheumatology (2025). High credibility.

The objective is to provide evidence-based and expert guidance for the screening, treatment, and management of lupus nephritis.

- **Methods**: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus of ≥ 70% on the direction (for or against) and strength (strong or conditional) of each recommendation.

- **Results**: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus-based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving a complete renal response.

- **Conclusion**: This guideline provides direction for clinicians regarding screening and treatment decisions for the management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^111Mwy14]. Arthritis Care & Research (2025). High credibility.

In the medical management of lupus nephritis, particularly concerning immunosuppressive therapy for class III-V LN, the ACR 2025 guidelines recommend considering the initiation of pulse IV corticosteroids at 250–1,000 mg of methylprednisolone daily for 1–3 days. This is followed by oral corticosteroids at ≤ 0.5 mg/kg/day, with a maximum dose of 40 mg/day, and a taper to a target dose of ≤ 5 mg/day by 6 months in patients experiencing an active, new-onset, or flare of class III/IV or class V LN. It is recommended to consider continuing therapy for at least 3–5 years in patients achieving or sustaining a complete renal response after treatment with any (triple or dual) immunosuppressive therapy.

---

### Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: A randomized, double-blind, placebo-controlled, phase II trial [^117Gx8yo]. Arthritis & Rheumatology (2023). High credibility.

To characterize its dose-response relationship, BI655064 — an anti-CD40 monoclonal antibody — was tested as an add-on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN).

- **Methods**: A total of 121 patients were randomized (2:1:1:2) to receive either a placebo or BI 655064 at doses of 120 mg, 180 mg, or 240 mg. Patients received a weekly loading dose for three weeks, followed by dosing every two weeks for the 120 mg and 180 mg groups, or 120 mg weekly for the 240 mg group. The primary endpoint was complete renal response (CRR) at week 52, with secondary endpoints including CRR at week 26.

- **Results**: A dose-response relationship with CRR at week 52 was not shown (BI 655064 120 mg, 38.3%; 180 mg, 45.0%; 240 mg, 44.6%; placebo, 48.3%). At week 26, 28.6% of patients receiving 120 mg, 50.0% receiving 180 mg, 35.0% receiving 240 mg, and 37.5% receiving placebo achieved CRR. The unexpectedly high placebo response prompted a post hoc analysis evaluating confirmed CRR (cCRR) at weeks 46 and 52. cCRR was achieved in 22.5% (120 mg), 44.3% (180 mg), 38.2% (240 mg), and 29.1% (placebo) of patients. Most patients reported at least one adverse event (BI 655064, 85.7–95.0%; placebo, 97.5%), most frequently infections and infestations (BI 655064 61.9–75.0%; placebo 60%). Compared with other groups, higher rates of serious (20% vs. 7.5–10%) and severe infections (10% vs. 4.8–5.0%) were reported with 240 mg BI 655064.

- **Conclusion**: The trial failed to demonstrate a dose-response relationship for the primary CRR endpoint. Post hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.

---

### Benlysta [^117FeEdT]. U.S. Food and Drug Administration (2024). High credibility.

In a randomized, double-blind, placebo-controlled, 104-week trial of active lupus nephritis in adults receiving Benlysta administered intravenously, serious infections occurred in 14% of patients receiving Benlysta and in 17% of patients receiving placebo. Fatal infections occurred in 0.9% (2/224) of patients receiving Benlysta and in 0.9% (2/224) of patients receiving placebo.

In a randomized, double-blind, placebo-controlled, 52-week, post-marketing safety trial of Benlysta administered intravenously in adults with SLE (N = 4,003), the incidence of serious infections was 3.7% in patients receiving Benlysta compared with 4.1% in patients receiving placebo. Serious infections leading to discontinuation of treatment occurred in 1.0% of patients receiving Benlysta and in 0.9% of patients receiving placebo. Fatal infections occurred in 0.45% (9/2,002) of patients receiving Benlysta and in 0.15% (3/2,001) of patients receiving placebo, where the incidence of all-cause mortality was 0.50% (10/2,002) in patients receiving Benlysta and 0.40% (8/2,001) in patients receiving placebo.

---

### Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial [^117DK7xC]. The Lancet Rheumatology (2024). High credibility.

Mycophenolate mofetil is an immunosuppressant commonly used to treat systemic lupus erythematosus (SLE) and lupus nephritis. It is a known teratogen associated with significant toxicities, including an increased risk of infections and malignancies. Withdrawal of mycophenolate mofetil is desirable once disease quiescence is achieved, but the timing and benefits of doing so have not been well-studied. This study aimed to determine the effects of mycophenolate mofetil withdrawal on the risk of clinically significant disease reactivation in patients with quiescent SLE on long-term therapy.

- **Methods**: This multicenter, open-label, randomized trial was conducted in 19 centers in the United States. Eligible patients were aged between 18 and 70 years, met the American College of Rheumatology (ACR) 1997 SLE criteria, and had a clinical SLEDAI score of less than 4 at screening. Mycophenolate mofetil therapy was required to be stable or decreasing for 2 years or more if initiated for renal indications, or for 1 year or more for non-renal indications. Participants were randomly allocated in a 1:1 ratio to either a withdrawal group, who tapered off mycophenolate mofetil over 12 weeks, or a maintenance group, who maintained their baseline dose (1–3g per day) for 60 weeks. Adaptive random allocation ensured groups were balanced for study site, renal versus non-renal disease, and baseline mycophenolate mofetil dose (≥ 2 g per day vs. < 2 g per day). Clinically significant disease reactivation by week 60 following random allocation required increased doses or adjustments.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^111LbAtp]. Arthritis Care & Research (2025). High credibility.

Regarding medical management for lupus nephritis, specifically concerning immunosuppressive therapy for class III-V LN, the ACR 2025 guidelines recommend the following therapies for patients with active/new-onset/flare of class III/IV, with or without class V, LN:

- **Mycophenolic acid analog-based regimen**: Prefer this over a cyclophosphamide-based regimen.

- **Triple immunosuppressive regimen containing mycophenolic acid analog plus calcineurin inhibitor**: Recommended for patients with proteinuria ≥ 3 g/g.

- **Triple immunosuppressive regimen containing belimumab**: Suitable for patients with extra-renal manifestations.

- **Euro LN Trial low-dose cyclophosphamide**: Preferred over a high-dose monthly pulse IV regimen in patients receiving a cyclophosphamide regimen.

- **Preference for Euro LN Trial low-dose cyclophosphamide**: Better over a daily oral cyclophosphamide regimen.

These recommendations aim to optimize treatment outcomes for lupus nephritis patients by tailoring immunosuppressive strategies according to individual patient profiles and clinical presentations.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^114CL2bD]. Arthritis Care & Research (2025). High credibility.

Regarding medical management for lupus nephritis, specifically with respect to immunosuppressive therapy, the general principles as outlined in the ACR 2025 guidelines recommend adjusting lupus nephritis medication dosage in patients with decreased glomerular filtration rate (GFR) at initiation and periodically during treatment.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^11596CBn]. Arthritis Care & Research (2025). High credibility.

The 2025 ACR guidelines on surgical interventions for lupus nephritis, specifically concerning kidney transplantation, recommend considering kidney transplantation in patients with lupus nephritis (LN) and end-stage renal disease (ESRD) without requiring complete clinical or serologic remission, provided there is no involvement of other major organs.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^112EVGo6]. Arthritis Care & Research (2025). High credibility.

Regarding medical management for lupus nephritis, particularly in relation to immunosuppressive therapy for Class III-V LN, the ACR 2025 guidelines recommend initiating prompt corticosteroid treatment in patients with suspected active LN to suppress acute inflammation while awaiting kidney biopsy and histopathology results.

---

### Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [^115WLtSL]. Arthritis and Rheumatism (1997). High credibility.

The clinical calculator for the "ACR classification criteria for lupus nephritis" is a tool designed to aid in diagnosing lupus nephritis in patients with systemic lupus erythematosus.

- **Primary components**: The ACR criteria include a diagnosis of systemic lupus erythematosus, urine 24-hour protein excretion greater than 0.5 g/day or a urine protein/creatinine ratio greater than 0.5 mg/mg, and urinary cellular casts of more than 5 cells per high-power field, in the absence of concomitant urinary infection. A patient meets the classification for lupus nephritis if they have a diagnosis of systemic lupus erythematosus and either significant proteinuria or urinary cellular casts; if not, the criteria are not fulfilled.

The ACR classification criteria for lupus nephritis is a valuable tool in the clinical setting, assisting clinicians in the accurate diagnosis and subsequent management of lupus nephritis in patients with systemic lupus erythematosus.

This calculator is designed to assess whether a patient meets the criteria for lupus nephritis according to the American College of Rheumatology (ACR) classification. The input consists of selecting criteria related to lupus nephritis, which include:

1. Diagnosis of systemic lupus erythematosus.
2. Urine 24-hour protein excretion greater than 0.5 g/day or urine protein/creatinine ratio greater than 0.5 mg/mg.
3. Presence of urinary cellular casts.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^113FjZUp]. Arthritis Care & Research (2025). High credibility.

The ACR 2025 guidelines recommend obtaining quantification of proteinuria every 3–6 months in patients with lupus nephritis who have sustained a complete renal response. This follow-up is crucial for surveillance and management of the condition.

---

### Current and emerging therapies for lupus nephritis [^114nSUGc]. Journal of the American Society of Nephrology (2016). Low credibility.

The introduction of corticosteroids and later, cyclophosphamide dramatically improved survival in patients with proliferative lupus nephritis, and combined administration of these agents became the standard-of-care treatment for this disease. However, treatment failures were still common, and the rate of progression to ESRD remained unacceptably high. Additionally, treatment was associated with significant morbidity. Therefore, as patient survival improved, the goals for advancing lupus nephritis treatment shifted to identifying therapies that could improve long-term renal outcomes and minimize treatment-related toxicity.

Unfortunately, progress has been slow and the approaches to the management of lupus nephritis continue to rely on high-dose corticosteroids plus a broad-spectrum immunosuppressive agent. Over the past decade, an improved understanding of lupus nephritis pathogenesis has fueled several clinical trials of novel drugs, but none have been found to be superior to the combination of a cytotoxic agent and corticosteroids. Despite these trial failures, efforts to translate mechanistic advances into new treatment approaches continue.

In this review, we discuss therapeutic strategies for lupus nephritis, briefly review recent advances in understanding the pathogenesis of this disease, and describe emerging approaches developed on the basis of these advances that promise to improve upon the standard-of-care lupus nephritis treatments.

---

### KDIGO 2024 clinical practice guideline for the management of lupus nephritis [^116J6pH1]. Kidney International (2024). High credibility.

Regarding medical management for lupus nephritis, specifically with respect to immunosuppressive therapy for class III-V LN, KDIGO 2024 guidelines recommend initiating corticosteroids plus any one of the following as initial therapy in patients with active class III or IV LN, with or without a membranous component:

- **A mycophenolic acid analog**: Therapy option when appropriate.

- **Low-dose IV cyclophosphamide**: An alternative initial therapy choice.

- **Belimumab and either a mycophenolic acid analog or low-dose IV cyclophosphamide**: Considered for certain patients based on their condition.

- **A mycophenolic acid analog and a calcineurin inhibitor**: Recommended when kidney function is not severely impaired (eGFR ≤ 45 mL/min/1.73 m²).

---

### 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [^117FVBEJ]. Annals of the Rheumatic Diseases (2020). High credibility.

Regarding medical management for lupus nephritis, specifically in relation to immunosuppressive therapy for class III-V lupus nephritis, the ERA-EDTA/EULAR 2020 guidelines recommend considering the initiation of high-dose intravenous cyclophosphamide (0.5–0.75 g/m² monthly for 6 months) in patients at high risk for kidney failure.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^114pjvrn]. Arthritis Care & Research (2025). High credibility.

Regarding therapeutic procedures for lupus nephritis, specifically concerning renal replacement therapy (RRT), the ACR 2025 guidelines recommend close collaboration with nephrology to determine the initiation and type of dialysis, as well as the timing for kidney transplantation.

---

### Comparison of quality-of-care measures in U.S. patients with end-stage renal disease secondary to lupus nephritis vs. other causes [^1156L2Dt]. BMC Nephrology (2015). Low credibility.

Being informed of transplant options, especially placement on the kidney transplant waitlist, increased over the study follow-up for patients with all attributed causes of ESRD; these secular trends have been previously noted in the U.S. LN-ESRD population. Changes in criteria for placement on the kidney transplant waitlist that have reduced racial disparities may have resulted in greater access to the waitlist among the minority LN-ESRD population. Additionally, increasing evidence that transplant outcomes among LN-ESRD and other ESRD patients appear to be equivalent may have contributed to this increase.

While both LN-ESRD and GN-ESRD patients were more likely to be placed on the kidney transplant waitlist than patients with other ESRD, the association was even stronger after the first year of ESRD among LN-ESRD patients. This may reflect recommendations to wait to transplant LN-ESRD patients to allow SLE activity to decrease. However, whether such delays are necessary or potentially even detrimental in this population remains in question.

---

### Bliss-ln trial revisited: function matters [^113vXHCK]. Kidney International (2022). Low credibility.

This post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN) shows belimumab effectively reduced the time to 30% and 40% decreases in estimated glomerular filtration rate and persistent decreases in estimated glomerular filtration rate. Subgroup analysis found belimumab was most effective in proliferative lupus nephritis, and that there was no apparent benefit from the addition of belimumab in those with baseline nephrotic range proteinuria nor in those receiving cyclophosphamide/azathioprine. These results raise questions about trial end points and their relationship to long-term kidney function, the outcome of most importance to patients, caregivers, and health professionals alike.

---

### The lupus nephritis management renaissance [^112yB3N3]. Kidney International (2022). Low credibility.

Over the past year, and for the first time ever, the US Food and Drug Administration approved two drugs specifically for the treatment of lupus nephritis (LN). As the lupus community works toward understanding how to best use these new therapies, it is also an ideal time to begin rethinking the overall management strategy of LN. In addition to new drugs, this must include how to use kidney biopsies for management and not just diagnosis, how molecular technologies can be applied to interrogate biopsies and how such data can impact management, and how to incorporate LN biomarkers into management paradigms. Herein, we will review new developments in these areas of LN and put them into perspective for disease management now and in the future.

---

### A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis [^116aicbP]. Kidney International (2022). High credibility.

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial. In this study, 448 patients with lupus nephritis were randomized to receive intravenous belimumab 10 mg/kg or placebo with standard therapy (cyclophosphamide/azathioprine or mycophenolate mofetil). Add-on belimumab was found to be most effective in improving the primary efficacy kidney response and complete kidney response in patients with proliferative lupus nephritis and a baseline urine protein/creatinine ratio under 3 g/g. However, there was no observed improvement in the kidney response with belimumab treatment in patients with lupus nephritis and sub-epithelial deposits or with a baseline protein/creatinine ratio of 3 g/g or more.

Belimumab significantly reduced the risk of kidney-related events or death and lupus nephritis flare in the overall population. It also reduced the risk of a sustained 30% or 40% decline in estimated glomerular filtration rate (eGFR) compared to standard treatment alone and attenuated the annual rate of eGFR decline in patients who remained on the study. Thus, our data suggest that the addition of belimumab to standard therapy could attenuate the risk of lupus nephritis flare and eGFR decline in a broad spectrum of patients with lupus nephritis.

---

### KDIGO 2024 clinical practice guideline for the management of lupus nephritis [^115ifgTd]. Kidney International (2024). High credibility.

Regarding medical management for lupus nephritis, specifically in relation to immunosuppressive therapy for pure class V LN, the KDIGO 2024 guidelines recommend initiating RAAS blockade and controlling BP in patients with pure class V LN.

---

### Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study [^111ymAws]. Rheumatology (2025). High credibility.

Treatment for lupus nephritis (LN) is largely based on histological class and activity. Patients with Class I and II may generally be monitored and do not need specific treatment unless presenting with nephrotic syndrome.

- **Guidelines for Class III and IV**:
	- Recommend combined immunosuppressives and glucocorticoids with or without belimumab (monoclonal antibody inhibiting B lymphocyte stimulator) or voclosporin (calcineurin inhibitor), administered as induction therapy followed by long-term maintenance therapy. The goals include reducing proteinuria, preserving kidney function, and preventing flares, while also reducing morbidity, mortality, and medication-induced toxicity.

- **Response to therapy**:
	- Stabilization or improvement in kidney function with a ≥ 50% reduction in proteinuria within the first 6 months has been identified as a strong prognostic indicator of long-term kidney survival, highlighting the benefit of tight disease control.

The combination of CYC or MMF/mycophenolic acid (MPA) with a high-dose glucocorticoid was previously the standard-of-care for patients with active LN. Globally, belimumab and voclosporin are approved in combination with standard-of-care immunosuppressive therapy for adults with active LN; these treatments were approved by the US Food and Drug Administration in 2020 and 2021, respectively. However, in phase 3 studies of these treatments, substantial proportions of patients did not achieve complete renal response (CRR). Thus, there remains a significant unmet need for therapies that can provide sustained remission in this patient population.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^113zAf2M]. Arthritis Care & Research (2025). High credibility.

Regarding medical management for lupus nephritis, and more specifically with respect to immunosuppressive therapy for class III-V LN, the ACR 2025 guidelines recommend considering the initiation of a triple immunosuppressive regimen. This includes pulse intravenous corticosteroids of 250–1,000 mg methylprednisolone daily for 1–3 days, followed by oral corticosteroids at ≤ 0.5 mg/kg/day (maximum dose 40 mg/day) with tapering. This regimen could be paired with the following options for patients with active, new-onset, or flare of class III/IV, with or without class V, lupus nephritis:

- **Mycophenolic acid analog plus belimumab**: To manage inflammation and immune response.

- **Mycophenolic acid analog plus calcineurin inhibitor**: Offering an alternative therapeutic approach.

- **Euro LN Trial low-dose cyclophosphamide plus belimumab**: Mycophenolic acid analog is substituted for cyclophosphamide after the cyclophosphamide course is complete.

---

### Benlysta [^116LCkRk]. U.S. Food and Drug Administration (2024). High credibility.

The odds ratio of PERR and CRR at week 104 across subgroups in Trial 5 is presented.

- **Subgroup classifications**: Class III refers to focal proliferative lupus nephritis, Class IV to diffuse proliferative lupus nephritis, Class V to membranous lupus nephritis, Class III + V to mixed membranous-focal proliferative lupus nephritis, and Class IV + V to mixed membranous-diffuse proliferative lupus nephritis.

- **Baseline analysis**: Baseline urine protein:creatinine ratio (uPCR) was assessed through a post-hoc analysis.

The proportion of responders for PERR by visit through week 104 is illustrated, highlighting primary efficacy renal response (PERR) with standard error by visit in adults with lupus nephritis.

- **PERR analysis**: This analysis is descriptive; bars indicate standard error. Note that the same patients may not have responded at every timepoint.

In Trial 5, subjects who received Benlysta were significantly less likely to experience a renal-related event or death compared with those who received a placebo.

Descriptive subgroup analyses of the time to a renal-related event or death revealed consistency with the overall endpoint regardless of induction therapy (mycophenolate or cyclophosphamide), biopsy class (Class III or IV, Class III + V or Class IV + V, or Class V), and baseline proteinuria (< 3 g/g or ≥ 3 g/g). These analyses were conducted post-hoc, and the treatment difference was primarily driven by the components of renal worsening and renal-related treatment failure within the endpoint.

---

### A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis [^116yp6Dz]. Arthritis & Rheumatology (2016). Low credibility.

An exploratory post hoc analysis was performed to examine baseline demographic and disease characteristics in responders and nonresponders in the sirukumab group, with response defined as a reduction in proteinuria of ≥ 50% from baseline at 2 or more visits through week 28. Of the 20 patients in the sirukumab group, 5 were classified as responders and 15 as nonresponders (see Supplementary Table 1, available on the Arthritis & Rheumatology website). Of these 5 responders, 3 were men (only 4 male patients were enrolled in the active treatment group), and 4 had class IV renal disease. In addition, 4 of the 5 responders had nonnephrotic levels of proteinuria (P:C ratio < 3) at baseline, and 3 were anti-dsDNA negative at baseline. Although these parameters appear to be enriched in this subset of responding patients, some of these features (nonnephrotic proteinuria levels, anti-dsDNA-negative status, and class IV renal disease) were also present in a number of nonresponders.

A retrospective analysis of serum IL-6 levels and the urine IL-6:creatinine ratios at screening (through week 0) and at week 24 was performed in sirukumab-treated responders compared with nonresponders. No trends were observed with regard to differences in serum IL-6 levels during screening or at week 24 between the responding and nonresponding patients (Table 3). At screening, serum IL-6 was undetectable in 15 of the 20 patients who received sirukumab. Serum IL-6 levels increased by week 24 in most of the sirukumab-treated patients, reflecting the binding of sirukumab to IL-6 and the complex remaining in circulation.

---

### Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria [^111HDbRR]. Clinical Journal of the American Society of Nephrology (2024). High credibility.

A ≥ 50% reduction in UPCR from baseline at any time during the study period was achieved in 97% and 75% of participants in the voclosporin and control arms, with median times to this endpoint of 29 and 58 days, respectively (HR, 2.12; 95% CI, 1.44 to 3.14; P < 0.001). Mean UPCR levels decreased over time in both arms, with lower mean values observed in the voclosporin arm at all time points after treatment initiation.

- **UPCR and eGFR over time**: Least squares mean of UPCR and corrected eGFR in participants with proliferative lupus nephritis and UPCR ≥ 3 g/g. Only participants with available data at the specified time points are included in the analyses. Baseline least squares means and 95% CIs are calculated from a model including a covariate for treatment group. Post-treatment least squares means and 95% CIs are calculated from a model including covariates for treatment group and baseline value. Renal function is assessed with corrected eGFR (Chronic Kidney Disease Epidemiology Collaboration equation) using a prespecified ceiling of 90 ml/min per 1.73 m².

Similar improvements in immunology parameters were observed in both arms.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^115wU4Yy]. Arthritis Care & Research (2025). High credibility.

For surgical interventions in lupus nephritis, particularly regarding kidney transplantation, the ACR 2025 guidelines suggest considering preemptive kidney transplantation rather than dialysis or non-preemptive transplantation. This recommendation applies to patients with lupus nephritis experiencing progressive kidney function loss and approaching end-stage renal disease, with an estimated glomerular filtration rate (eGFR) of ≤ 15 mL/min/1.73 m².

---

### A review of the AURORA and BLISS trials: Will it revolutionize the treatment of lupus nephritis [^117EcucD]. Current Opinion in Nephrology and Hypertension (2022). Low credibility.

Renal involvement in patients with systemic lupus erythematosus can lead to significant complications, including end-stage renal disease. Treatment of lupus nephritis has evolved over the last several decades. Despite this evolution, many patients fail to achieve remission and often progress to end-stage kidney disease or experience adverse side effects related to treatment.

Recent findings from the AURORA 1 and BLISS LN trials led the FDA to approve voclosporin and belimumab for the treatment of lupus nephritis. The AURORA 1 trial demonstrated that voclosporin, a second-generation calcineurin inhibitor, effectively lowers proteinuria in patients with lupus nephritis when added to mycophenolate mofetil, with a better safety profile compared to other calcineurin inhibitors. The BLISS LN trial revealed better control of disease and a lower risk of progression to end-stage kidney disease (ESKD) and relapses in patients treated with belimumab in addition to standard therapy.

Both voclosporin and belimumab are costly and have not shown any early evidence to revolutionize practice in the management of lupus nephritis. Until more data are made available from future studies or other cost-effective treatment options become available, the widespread adoption and utility of these novel agents remain limited.

---

### Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [^116UeiQc]. Arthritis & Rheumatology (2021). High credibility.

This study was sponsored by Genentech, Inc, which provided the study medication and some financial support. However, Genentech, Inc. had no role in the study design, data collection, analysis, interpretation, writing of the manuscript, or the decision to submit the manuscript for publication. Importantly, the publication of this article was independent and not contingent upon approval by Genentech, Inc.

---

### 2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis [^114kbPAG]. Annals of the Rheumatic Diseases (2020). High credibility.

Regarding diagnostic procedures for lupus nephritis, specifically concerning kidney biopsy, the ERA-EDTA/EULAR 2020 guidelines recommend considering a kidney biopsy if there is evidence of kidney involvement. This is particularly suggested in the presence of persistent proteinuria ≥ 0.5 g/24 hours or a urine protein-to-creatine ratio ≥ 500 mg/g in morning first void urine, and/or an unexplained decrease in GFR.

---

### Systematic review and meta-analysis of clinical outcomes comparison between different initial dialysis modalities in end-stage renal disease patients due to lupus nephritis prior to renal transplantation [^116bUQtK]. BMC Nephrology (2020). Low credibility.

- **Methods**: The protocol for this study was registered at PROSPERO 2019 CRD42019131600 and it can be found via the following link.

- **Eligibility criteria**: This study included participants with ESRD (i.e. eGFR of lower than 15 mL per minute per 1.73 square meters) due to lupus nephritis, receiving either of the two initial RRT modalities, namely hemodialysis or peritoneal dialysis, prior to renal transplant. Both adult (i.e. 18 years or older) and pediatric (i.e. younger than 18 years old) participants were eligible for inclusion. The main outcomes were risks of lupus flare, all-cause infections, all-cause cardiovascular events, and mortality. Both prospective and retrospective matched case-control studies comparing the suitable outcomes between the two initial dialysis modalities in LN-ESRD were eligible for inclusion. To increase the external validity of this study, accessible literature from all around the world was eligible for inclusion. Only English publications were eligible for inclusion.

- **Information sources**: The three online databases, namely PubMed, EMBASE, and Scopus, were searched to identify eligible studies. The searches were not limited to any specific date ranges. Secondary referencing of eligible studies was done to extend the search scope. The last date of the search was 28th September 2019.

- **The search**: To generate a set of citations relevant to our study's search question, an advanced search tool was used in all three of the aforementioned databases. Using PubMed, the MeSH search builder was utilized.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^111oaQGU]. Arthritis Care & Research (2025). High credibility.

Regarding surgical interventions for lupus nephritis, specifically concerning kidney transplantation, the ACR 2025 guidelines recommend obtaining regular follow-up with rheumatology for patients with lupus nephritis after kidney transplantation.

---

### KDIGO 2024 clinical practice guideline for the management of lupus nephritis [^111H72of]. Kidney International (2024). High credibility.

Regarding surgical interventions for lupus nephritis, more specifically with respect to kidney transplantation, KDIGO 2024 guidelines suggest offering kidney transplantation, which is preferred over long-term dialysis, in patients who have developed kidney failure due to lupus nephritis.

---

### Safety and clinical efficacy of relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial [^114Xrc7A]. EClinicalMedicine (2025). High credibility.

The exclusion criteria mainly include having severe lupus nephritis within 8 weeks prior to screening that requires treatment for active nephritis with protocol-prohibited medications, or requiring dialysis, or receiving prednisone ≥ 100 mg/day or equivalent corticosteroids for ≥ 14 days. Meanwhile, patients who received the following treatments before treatment are excluded:

1. Therapeutic doses of glucocorticoids (prednisone or equivalent > 20 mg/day) within 7 days before leukapheresis or within 72 hours before infusion of relma-cel.
2. Use of any other clinical investigational drug for SLE within 4 weeks before leukapheresis; however, subjects may be enrolled if the treatment during the study is ineffective or the disease progresses, and at least 3 half-lives have passed before leukapheresis.
3. Use of anti-CD20 monoclonal antibodies (e.g. rituximab), telitacicept, or belimumab within 7 days before leukapheresis or 4–6 weeks before infusion of relma-cel.
4. Prior CAR-T cell therapy or other genetically modified T cell therapies.

Patients with other lupus-related crises, such as active central nervous system lupus, severe lupus pneumonitis, or pulmonary hemorrhage, are also excluded. More detailed inclusion and exclusion criteria were presented in the supplementary material.

After enrollment, leukapheresis was performed to collect peripheral blood mononuclear cells (PBMCs), which are then transported to a central manufacturing facility for the production of relma-cel. Relma-cel consists of autologous CD4+ and CD8+ T cells genetically modified to express a CD19.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^115VmtZJ]. Arthritis Care & Research (2025). High credibility.

The objective is to provide evidence-based and expert guidance for the screening, treatment, and management of lupus nephritis.

- **Methods**: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus of ≥ 70% on the direction (for or against) and strength (strong or conditional) of each recommendation.

- **Results**: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus-based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.

- **Conclusion**: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual.

---

### Predictors of long-term renal outcome in lupus nephritis trials: Lessons learned from the Euro-Lupus Nephritis cohort [^1116uvNA]. Arthritis & Rheumatology (2015). Low credibility.

There is a need to determine which response measures in lupus nephritis trials are most predictive of good long-term renal function. We used data from the Euro-Lupus Nephritis Trial to evaluate the performance of proteinuria, serum creatinine (Cr), and urinary red blood cells (RBCs) as predictors of good long-term renal outcome.

- **Methods**: Patients from the Euro-Lupus Nephritis Trial with proteinuria, serum Cr, and urinary RBC measurements at 3, 6, or 12 months and with a minimum of 7 years of follow-up were included (n = 76). We assessed the ability of these clinical biomarkers at 3, 6, and 12 months after randomization to predict good long-term renal outcome (defined as a serum Cr value ≤ 1.0 mg/dl) at 7 years. Receiver operating characteristic curves were generated to assess parameter performance at these time points and to select the best cutoff for individual parameters. Sensitivity and specificity were calculated for the parameters alone and in combination.

- **Results**: A proteinuria value of < 0.8 gm/day at 12 months after randomization was the single best predictor of good long-term renal function (sensitivity 81% and specificity 78%). The addition of serum Cr to proteinuria as a composite predictor did not improve the performance of the outcome measure; addition of urinary RBCs as a predictor significantly decreased the sensitivity to 47%.

- **Conclusion**: This study demonstrates that the level of proteinuria at 12 months is the individual best predictor of long-term renal outcome in patients with lupus nephritis. Inclusion of urinary RBCs as part of a composite output decreased the overall accuracy.

---

### Efficacy of voclosporin in proliferative lupus nephritis with high levels of proteinuria [^111xQ3p4]. Clinical Journal of the American Society of Nephrology (2024). High credibility.

As a post hoc analysis of the AURORA 1 trial, this study was not powered to detect differences in treatment outcomes for this subset of patients. Despite this and a lack of randomization specific to those with proliferative lupus nephritis and high levels of proteinuria, the analysis remains informative and clinically relevant. It is reassuring that when analyses were applied to the AURORA 1 cohort with proteinuria < 3 g/g, the results were similar with a smaller effect size.

AURORA 1 was a global study that enrolled a diverse population of participants across races, ethnicities, and geographical regions, many of which have been associated with lower rates of renal response. Despite the study including many patient populations traditionally considered more difficult to treat, there was a significant benefit reported with voclosporin in this substudy of patients with proliferative lupus nephritis and high levels of proteinuria, providing evidence of the drug's benefit across the clinical spectrum.

Study participants with proliferative lupus nephritis and high levels of proteinuria treated with voclosporin, in combination with MMF and low-dose glucocorticoids, demonstrated significantly earlier reductions in proteinuria and higher rates of complete renal response compared to those treated with MMF and low-dose glucocorticoids alone over a 12-month period. Similar safety outcomes were reported in both the treatment and control arms. This analysis suggests that voclosporin is an effective therapy in this patient population.

---

### A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis [^112CfEid]. Arthritis & Rheumatology (2016). Low credibility.

- **Results: Disposition and baseline characteristics of the patients**: Sixty-two patients from 18 sites in 6 countries were screened. Of these, 25 were randomized to receive either placebo (n = 4) or sirukumab (n = 21). Among all randomized patients, 6 (24.0%), all in the sirukumab group, discontinued the study agent before week 24 — 5 due to adverse events (AEs), while 1 patient withdrew consent on day 2 before any efficacy data or serum samples were collected. Thus, 19 patients (76.0%) completed treatment through week 24. In total, 20 (80.0%) of the 25 randomized patients continued study participation through week 40, including the 16-week follow-up.

The majority of the study population were female (84.0%), with a mean age of 32 years. The demographic characteristics of the patients were generally similar between the two treatment groups, except that all 4 placebo-treated patients were female, 3 (75.0%) of the 4 placebo-treated patients were Asian, and patients in the placebo group were slightly older than those in the sirukumab group (mean age 37.8 years versus 30.6 years).

Baseline features of disease were comparable between the two treatment groups, with the exception of the duration of SLE (mean 8.1 years in the sirukumab group and 6.5 years in the placebo group). Mean SLEDAI-2K scores at baseline were consistent, showing moderately high disease activity in both groups, which could be attributed to the weighting of active renal disease in the SLEDAI-2K score.

---

### 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis [^112ocfpB]. Arthritis Care & Research (2025). High credibility.

Regarding follow-up and surveillance for lupus nephritis, specifically in relation to follow-up, the ACR 2025 guidelines recommend obtaining serum complement levels and anti-double-stranded DNA antibody concentrations at every clinic visit, but not more frequently than monthly.